share_log

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

Intelligent Bio Solutions | 8-K: Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights

Intelligent Bio Solutions | 8-K：智能生物解决方案公布2025财年第一季度财务业绩和运营亮点
美股SEC公告 ·  2024/11/07 17:19

Moomoo AI 已提取核心信息

Intelligent Bio Solutions achieved 10% YoY revenue growth to $0.87 million in fiscal Q1 2025, marking its fourth consecutive quarter of growth. Higher-margin cartridge sales surpassed reader revenue, with international sales increasing by 15%. The company secured 22 new accounts, expanding its presence to over 400 active customers across 19 countries.The company completed the in-clinic portion of its FDA 510(k) clinical study plan and is on track for FDA submission by end-2024. Initial pharmacokinetic study results indicate strong correlation between fingerprint sweat and traditional testing methods, with full results expected in November. The company aims to enter the US market in the first half of 2025.Financial results showed a net loss of $2.70 million, including $0.49 million in non-cash expenses. Cash position remained strong at $3.99 million, with shareholders' equity at $5.95 million as of September 30, 2024. The increased net loss reflects investments in R&D for FDA 510(k) clinical studies.
Intelligent Bio Solutions achieved 10% YoY revenue growth to $0.87 million in fiscal Q1 2025, marking its fourth consecutive quarter of growth. Higher-margin cartridge sales surpassed reader revenue, with international sales increasing by 15%. The company secured 22 new accounts, expanding its presence to over 400 active customers across 19 countries.The company completed the in-clinic portion of its FDA 510(k) clinical study plan and is on track for FDA submission by end-2024. Initial pharmacokinetic study results indicate strong correlation between fingerprint sweat and traditional testing methods, with full results expected in November. The company aims to enter the US market in the first half of 2025.Financial results showed a net loss of $2.70 million, including $0.49 million in non-cash expenses. Cash position remained strong at $3.99 million, with shareholders' equity at $5.95 million as of September 30, 2024. The increased net loss reflects investments in R&D for FDA 510(k) clinical studies.
智能生物解决方案在2025财年第一季度实现了10%的同比营业收入增长，达到了87万美元，标志着其连续第四个季度增长。高利润率的耗材销售超过了读取器收入，国际销售增长了15%。公司新增了22个账户，使其在19个国家的活跃客户超过400个。公司完成了FDA 510(k)临床研究计划的临床部分，并计划在2024年底前向FDA提交。初步药代动力学研究结果显示，指纹汗液与传统检测方法之间存在强关联，完整结果预计在11月份发布。公司计划在2025年上半年进入美国市场。财务结果显示净亏损为270万美元，其中包括49万美元的非现金费用。现金状况仍然强劲，截止到2024年9月30日，现金余额为399万美元，股东权益为595万美元。净亏损的增加反映了对FDA 510(k)临床研究的研发投资。
智能生物解决方案在2025财年第一季度实现了10%的同比营业收入增长，达到了87万美元，标志着其连续第四个季度增长。高利润率的耗材销售超过了读取器收入，国际销售增长了15%。公司新增了22个账户，使其在19个国家的活跃客户超过400个。公司完成了FDA 510(k)临床研究计划的临床部分，并计划在2024年底前向FDA提交。初步药代动力学研究结果显示，指纹汗液与传统检测方法之间存在强关联，完整结果预计在11月份发布。公司计划在2025年上半年进入美国市场。财务结果显示净亏损为270万美元，其中包括49万美元的非现金费用。现金状况仍然强劲，截止到2024年9月30日，现金余额为399万美元，股东权益为595万美元。净亏损的增加反映了对FDA 510(k)临床研究的研发投资。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Pacific Biosciences of California
    PACB
    -- 1.850
    Avita Medical
    RCEL
    -- 10.570
    PAVmed
    PAVM
    -- 0.7900
    古特拉
    CUTR
    -- 0.481
    Lifeward
    LFWD
    -- 2.185
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！